Minimal dataset for post-registration surveillance of new drugs in haemophilia: communication from the SSC or the ISTH

Peyvandi, F, Makris, M, Collins, Peter ORCID: https://orcid.org/0000-0002-6410-1324, Lillicrap, D, Pipe, S.W., Iorio, A and Rosendaal, F.R. 2017. Minimal dataset for post-registration surveillance of new drugs in haemophilia: communication from the SSC or the ISTH. Journal of Thrombosis and Haemostatis 15 (9) , pp. 1878-1881. 10.1111/jth.13762

Preview

PDF - Accepted Post-Print Version Download (100kB) | Preview

Abstract

The term ‘postmarketing surveillance’ refers to analyses for the purpose of detecting adverse drug reactions in data accumulated after a medicinal product has been authorized by a regulatory agency [1-3]. The current regulatory process has systematic provisions for obtaining important data needed to ensure the safety of novel drugs almost exclusively during premarketing testing [4]. However, premarketing trials frequently do not have sufficient power to reliably detect important adverse drug reactions [5].

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	Haemophilia; Factor VIII; Factor IX; replacement products; inhibitors; side effects
Publisher:	Wiley-Blackwell
ISSN:	1538-7933
Date of First Compliant Deposit:	29 June 2017
Date of Acceptance:	18 June 2017
Last Modified:	04 Dec 2024 21:15
URI:	https://orca.cardiff.ac.uk/id/eprint/101891

Citation Data

Cited 10 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item